New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 17, 2014
11:37 EDTMDT, EWEdwards Lifesciences weakness a buying opportunity, says Canaccord
Canaccord said Edwards Lifesciences is down following Metronic's (MDT) FDA approval for the CoreValve TAVI system, which was a few months earlier than expected but in line with guidance. The analyst continues to expect the FDA's approval of Edwares Lifesciences' SAPIEN XT by mid-2014 but could actually be sooner following the Medtronic's approval. The firm continues to recommend Edwards Lifesciences and reiterates its Buy rating and $78 price target.
News For EW;MDT From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
July 22, 2015
10:15 EDTMDTThoratec downgraded to Market Perform from Outperform at Northland
Subscribe for More Information
July 17, 2015
08:07 EDTMDTMedtronic shares undervalued, says Wells Fargo
Subscribe for More Information
July 16, 2015
10:00 EDTMDTOn The Fly: Analyst Upgrade Summary
Today's noteworthy upgrades include: Arc Logistics (ARCX) upgraded to Buy from Hold at Stifel... Dean Foods (DF) upgraded to Buy from Hold at Deutsche Bank... FreightCar America (RAIL) upgraded to Neutral from Sell at UBS... Frontier Communications (FTR) upgraded to Buy from Hold at Jefferies... Google (GOOG) upgraded to Outperform from Market Perform at BMO Capital... Intel (INTC) upgraded to Buy from Hold at Needham... Medtronic (MDT) upgraded to Buy from Neutral at BTIG... Netflix (NFLX) upgraded to Buy from Neutral at Rosenblatt... New Jersey Resources (NJR) upgraded to Buy from Hold at Argus... ONEOK Partners (OKS) upgraded to Outperform from Perform at Oppenheimer... Patterson-UTI (PTEN) upgraded to Overweight from Equal Weight at Morgan Stanley... SJM Holdings (SJMHY) upgraded to Overweight from Underweight at JPMorgan... Statoil (STO) upgraded to Buy from Neutral at Citi... SunOpta (STKL) upgraded to Outperform from Sector Perform at Scotia Howard Weil... Viacom (VIAB) upgraded to Neutral from Sell at Citi... Walgreens Boots Alliance (WBA) upgraded to Outperform from Neutral at Credit Suisse... Werner (WERN) upgraded on 'compelling' valuation at Wells Fargo... Wisconsin Energy (WEC) upgraded to Outperform from Neutral at Baird... voxeljet (VJET) upgraded to Overweight from Neutral at Piper Jaffray.
07:42 EDTMDTMedtronic upgraded to Buy from Neutral at BTIG
BTIG upgraded Medtronic to Buy with a $89 price target. The firm believes the recent pullback has provided a buying opportunity and views the company as well positioned for growth with revenue upside, strong cash deployment, and more Covidien synergies than some expect.
05:54 EDTMDTMedtronic recalls Shiley neonatal, pediatric tracheostomy tubes
Subscribe for More Information
July 15, 2015
07:29 EDTMDTAmerican Orthopaedic Foot & Ankle Society to hold annual meeting
Subscribe for More Information
July 13, 2015
19:23 EDTEWEdwards Lifesciences holders should expect gains from acquisition, Barron's says
Edwards Lifesciences acquired CardiAQ and received two upgrades; shareholders should expect more gains, despite the stock's expensive price, Barron's contends in its 'Barron's Take' column. Reference Link
10:21 EDTEWOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
08:44 EDTMDTMedtronic to acquire RF Surgical Systems for about $235M
Medtronic announced it has signed a definitive agreement to acquire RF Surgical Systems, a medical device company based in Carlsbad, CA, focused on the detection and prevention of retained surgical items for approximately $235M. Additional terms of the acquisition were not disclosed.
08:41 EDTEWEdwards Lifesciences upgraded to Outperform from Market Perform at Northland
Northland upgraded Edwards Lifesciences to Outperform citing the acquisition of CardiAQ, an early-stage company developing a TMVI system. The firm views the acquisition as a smart as it jump starts the TMVI program and adds a wealth knowledge from the principals who have a prior background at CoreValue. Northland increased Edwards Lifesciences' price target to $170 from $140 on shares.
07:48 EDTEWCanaccord recommends Edwards Lifesciences, Neovasc in TMVR sector
Canaccord said they continue to like both Edwards Lifesciences (EW) and Neovasc (NVCN) in the transcatheter mitral valve replacement, or TMVR, space. The firm sees long term growth potential in the TMVR space and upside earnings and revenue potential in Edwards due to its leverage there and its acquisition of privately held CardiAQ. The firm said the removal of CardiAQ as a competitor should be positive for Neovasc and has a Buy rating on both stocks.
07:02 EDTEWEdwards Lifesciences upgraded to Outperform from Sector Perform at RBC Capital
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use